Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer’s NDA for dual Src and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML bypassed the failed first-line Phase III BELA trial. In Europe, BELA is the basis of a pending front-line CML application.

You may also be interested in...



Pfizer’s Bosulif Will Face Competitive Market In Second-Line CML

Approved by FDA Sept. 4, bosutinib will face off against two established tyrosine kinase inhibitors in the post-Gleevec treatment setting: Bristol’s Sprycel and Novartis’ Tasigna. Pfizer is highlighting Bosulif’s “distinct adverse event profile” and single-daily dosing to its advantage.

Pfizer Prices Bosulif With Eye Towards Leveling CML Playing Field

Pfizer enters crowded competition for previously treated Ph+ chronic myelogenous leukemia with the newly approved bosutinib, but the firm hopes having a comparable price will level the playing field.

Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel